Sign In
Buy APLT
$0.0959
+0 (+0%)
At Close: Apr 28, 2026
Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia
07:00am, Thursday, 17'th Jun 2021
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec
Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference
07:00am, Wednesday, 19'th May 2021
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecu
Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences
07:00am, Tuesday, 23'rd Feb 2021
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec
Applied Therapeutics, Inc. Announces Closing of Public Offering
07:00am, Monday, 22'nd Feb 2021
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates aga
Applied Therapeutics Raises $69M Via Equity
08:13am, Friday, 12'th Feb 2021
Applied Therapeutics Inc (NASDAQ: APLT) prices its underwritten public offering of 3 million at $23 per share, raising $69 million in gross proceeds, at a marginal premium of 2%. Underwriters have
Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock
06:51pm, Thursday, 11'th Feb 2021
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates aga
Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares of Common Stock
04:07pm, Wednesday, 10'th Feb 2021
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates aga
Applied Therapeutics Announces Restart of Pediatric Galactosemia Study
07:00am, Monday, 01'st Feb 2021
FDA Clinical Hold Lifted
Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative
08:15am, Wednesday, 09'th Dec 2020
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec
Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study
07:00am, Wednesday, 09'th Dec 2020
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec
Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) Treatment with AT-001 normalizes cardiac energetics and improves ca
Irish Airport Retailer ARI Extends Global Footprint To Montenegro And Invests Online
12:00am, Thursday, 08'th Oct 2020
Aer Rianta International is pushing forwards during the pandemic as a safeguard for the long term, helped by a strong balance sheet, according to its CEO.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
11:35pm, Wednesday, 19'th Aug 2020
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.
EQUITY ALERT: ROSEN, A LEADING AND RANKED LAW FIRM, Announces Investigation of Securities Claims Against Applied Therapeutics, Inc. – APLT
01:55pm, Wednesday, 19'th Aug 2020
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from alleg
